Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 5, 2025Hematology

The promise of menin inhibitors: from approval to triplet regimens

View Full Paper
Ask AI
Bookmark
Share

Authors

RTRahul K. ThakurEWEunice S. Wang

Discussion

Loading...

Member takes

Overview

Findings indicate menin inhibitors improve response rates in acute myeloid leukemia, suggesting their role in treatment regimens.

Key Points

  • Acute myeloid leukemia patients showed improved overall response rates with menin inhibitors, highlighting efficacy.
  • Critical clinical findings report response rates between 45-65% in heavily pretreated KMT2Ar and NPM1m AML patients.
  • Assessment reveals the combination of menin inhibitors with anthracycline or venetoclax enhances treatment options significantly.
  • These results support the incorporation of menin blockade in frontline and maintenance regimens for AML patients.

Cite This Study

Thakur et al. (2025) studied this question.

synapsesocial.com/papers/6940224e2d562116f28fc0fdhttps://doi.org/10.1182/hematology.2025000755
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Top advances of the year: Acute myeloid leukemia2025 · 5 citations
  2. 2Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study2023 · 32 citations
  3. 3A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition2022 · 88 citations